Collegium Pharmaceutical (COLL) PT Raised to $28.00 at Needham & Company LLC
Collegium Pharmaceutical (NASDAQ:COLL) had its target price raised by analysts at Needham & Company LLC from $25.00 to $28.00 in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 65.29% from the company’s current price. The analysts noted that the move was a valuation call.
Other analysts also recently issued research reports about the stock. Jefferies Group lifted their target price on shares of Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a report on Tuesday. Piper Jaffray Companies set a $19.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, November 29th. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, November 17th. Finally, Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Monday, November 13th. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $22.67.
Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $16.94 on Tuesday. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $19.21.
In other Collegium Pharmaceutical news, insider Alison B. Fleming sold 4,601 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total value of $79,367.25. Following the completion of the transaction, the insider now owns 28,513 shares in the company, valued at $491,849.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the transaction, the chief executive officer now owns 558,987 shares of the company’s stock, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,630 shares of company stock valued at $924,360. Insiders own 25.76% of the company’s stock.
Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Collegium Pharmaceutical by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock worth $8,113,000 after purchasing an additional 58,398 shares during the last quarter. Teton Advisors Inc. purchased a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth $283,000. Bank of New York Mellon Corp lifted its position in shares of Collegium Pharmaceutical by 60.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock worth $1,313,000 after purchasing an additional 39,656 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 98.8% during the 2nd quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock worth $745,000 after purchasing an additional 29,617 shares during the last quarter. Finally, Pier Capital LLC lifted its position in shares of Collegium Pharmaceutical by 8.1% during the 2nd quarter. Pier Capital LLC now owns 395,658 shares of the specialty pharmaceutical company’s stock worth $4,950,000 after purchasing an additional 29,594 shares during the last quarter. Institutional investors and hedge funds own 79.98% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.